CAR-T cells (Chimeric Antigen Receptor T cells) is an emerging immunotherapy technology that has emerged in recent years. CAR-T cells are a new generation of cell therapy technology that expresses chimeric antigen receptors on the surface of T cells to form a targeted therapy that overcomes the immune escape of tumors. CAR-T cells have excellent advantages that other immunotherapies do not have, and they can survive in the body for a long time and have the ability to completely eliminate tumor cells. Currently, clinical treatment studies in the United States, Europe, Australia and other countries and regions have achieved exciting therapeutic results by applying CAR-T cells targeting CD19 and CD20 for lymphoma and leukemia, targeting CD138 for multiple myeloma, targeting GD2 for neuroblastoma, targeting CEA for gastric, colorectal and breast cancers, and targeting HER2 for lung cancer, etc. The results are encouraging. In particular, CAR-T therapy targeting CD19 molecules has been widely used to cure many patients with relapsed and refractory leukemia and lymphoma, and the application of CAR-T cells to treat leukemia and lymphoma has achieved great success. In March 2013, two children with ALL (acute gonorrhea leukemia), were treated with CAR-T cells targeting the CD19 antigen, one of whom was 7-year-old Emily Whitehead, a little girl received CAR-T cell therapy after relapsing on conventional therapy and went into complete remission, and nearly 30 months after receiving this T-cell therapy, Emily remains healthy with no signs of leukemia relapse. At the 2014 ASH meeting, Sadelain and colleagues reported that treatment of six lymphoma patients with CAR-T cells resulted in the complete disappearance of clinical manifestations of the tumor in all patients; Carl H. June reported that CAR-T cell therapy targeting CD19 resulted in significant reductions in tumor cells in nine of 23 patients with chronic lymphocytic leukemia and 30 patients with malignant acute The Stephan team at Philadelphia University used CAR-T cells targeting CD19 to treat more than 60 patients with relapsed acute and slow onset gonorrhea with a 90% remission rate; the NCI’s CAR-T cell therapy has been hailed as the ultimate therapy for tumors and has sounded the true call for a cure. Malignant tumor is one of the major major diseases that endanger human health. With the advancement of modern medicine and the application of comprehensive means including surgery, chemotherapy and radiotherapy, great progress has been made in the treatment of tumors. However, due to the lack of targeting of the above-mentioned traditional treatments, which can cause great damage to the normal tissues of the body, the efficacy of treatment for malignant tumors is still very unsatisfactory in general. Patients with malignant tumors still mostly die after treatment due to tumor resistance, recurrence and metastasis. Therefore, on the basis of studying the mechanism of tumor development, seeking the application of targeted gene therapy and immunotherapy to overcome tumors has become one of the main development directions of modern medicine. The CD19-CAR-T cell therapy for relapsed/refractory leukemia and lymphoma has been a great success in overseas clinical trials, and our department has completed the preliminary research of this technology and is expected to take the lead in building It is expected to be the first clinical research base of CAR-T cell immunotherapy for leukemia and lymphoma in China.